GlassScriptPhysician profile
Dylan M Thiel
NPI 1376040113
$2,835.98
in general payments reported to CMS, 2019-2025
22 companies · $630 in 2025
The $630 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $246 · 2021: $283 · 2022: $464 · 2023: $406 · 2024: $807 · 2025: $630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,825 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,825.14 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $477.36 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $401.78 | 2022-2025 | Tezspire, Fasenra, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $320.48 | 2021-2025 | Ofev |
| Inari Medical, INC. | $286.81 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Insmed, INC. | $263.74 | 2022-2025 | Arikayce, Brinsupri |
| United Therapeutics Corporation | $203.71 | 2023-2025 | Remodulin, Orenitram, Tyvaso |
| Genentech USA, INC. | $133.08 | 2019 | |
| Abiomed | $125.33 | 2024 | Impella |
| Inspire Medical Systems, INC. | $117.84 | 2023 | Inspire |
| Regeneron Healthcare Solutions, INC. | $106.49 | 2025 | Dupixent |
| Merck Sharp & Dohme LLC | $70.89 | 2024-2025 | Keytruda, Winrevair, Zerbaxa |
| Amgen INC. | $70.44 | 2022-2024 | Tezspire |
| Grifols USA, LLC | $44.39 | 2024 | Prolastin-C Liquid |
| Verona Pharma, INC. | $43.19 | 2025 | Ohtuvayre |
| Genzyme Corporation | $38.99 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $31.71 | 2025 | Glassia |
| Jazz Pharmaceuticals INC. | $19.23 | 2023 | |
| Csl Behring | $17.58 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.57 | 2024 | |
| Philips North America LLC | $17.19 | 2021 | |
| Haemonetics Corporation | $15.78 | 2022 | |
| Inogen, INC. | $12.40 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dylan Thiel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.